Key clinical point: There may be an overall survival benefit of combining human papillomavirus vaccination with standard-of-care chemotherapy for cervical cancer.
Major finding: The median overall survival was 16.8 months for patients with immune responses to the vaccine that were higher than the median and 11.2 months for patients with immune responses lower than the median (hazard ratio, 0.491; P = .012).
Study details: A phase 1/2 study of 77 women with HPV16-positive advanced, metastatic, or recurrent cervical cancer.
Disclosures: The study was funded by ISA Pharmaceuticals and a Dutch Cancer Society grant. Investigators disclosed relationships with ISA Pharmaceuticals and other companies.
Melief CJM et al. Sci Transl Med. 2020;12:eaaz8235.